Article
BRAF V600E-induced distinct DNA damage response defines the therapeutic potential of p53 activation for TP53 wild-type colorectal cancer.
Carcinogenesis - 22 Nov 2024
Tokuyama Shinji, Kato Hisakazu, Takahashi Hidekazu, Ueda Kyoko, Arita Asami, Ueda Ryuta, Seto Hiroto, Sekido Yuki, Hata Tsuyoshi, Hamabe Atsushi, Ogino Takayuki, Miyoshi Norikatsu, Uemura Mamoru, Matsuoka Ken, Tsukamoto Osamu, Yamamoto Hirofumi, Doki Yuichiro, Eguchi Hidetoshi, Takashima Seiji
Abstract excerpt
BRAF V600E, one of the most frequent mutations in the MAPK pathway, confers poor prognosis to colorectal cancers (CRCs), partly because of chemotherapeutic resistance. Oncogene-induced DNA damage responses (DDRs) that primarily activate p53 are important mechanistic barriers to the malignant transformation of cells; however, the mechanism underlying this impairment in cancer remains unknown. Here, we evaluated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.